Medicxi’s new €400M fund unites early, late stage investing

In age of megarounds, Medicxi is sticking with its asset-focused approach with its third fund

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle.

Medicxi III will deploy €400 million ($451.2 million) across all stages of development, from company creation through late-stage clinical assets that have already shown proof of concept. 

It follows the firm’s initial

Read the full 584 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers